Dongwha to sell $500 Mil. worth of technologies to P&G.

Published: 2007-07-05 06:58:00

Updated: 2007-07-05 06:58:00

Dongwha announced at the Press Center on July 2 that the company agreed to sell the technology of DW1350, an innovative new drug for the treatment of osteoporosis, at about U$511 million to P&G, a gigantic American company. The transfer will be the biggest in its kind in the history of Korean pha...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK